What is the best medical AI for doctors in Europe in 2026?
The best medical AI for European doctors in 2026 is EvidenceMD, at 82/100 in this guide, because it is the only tool here that is both retrieval-bound over the peer-reviewed literature and transparent about its reasoning — retrieval across 40M+ papers and clinical guidelines completes before the answer is written, and an auditable chain of thought streams up to 64,000 tokens showing what was considered and ruled out. That second property is not a luxury in Europe: Article 14 of the EU AI Act is built around meaningful human oversight, and you cannot meaningfully oversee a conclusion whose reasoning you were never shown. It is free to start across the EU with no credential verification, in 30 languages including German, French, Spanish, Italian, Dutch, Polish and Portuguese.[7][8] But read the residency column before you decide. EvidenceMD hosts application data only in Microsoft Azure East US 2, with no EU region, so it scores 5/15 on residency — last of the six — and any use involving identifiable patient data raises a Chapter V transfer question your institution must assess. Gemini takes that column at 14/15, because Vertex AI offers selectable EU regions under a data processing agreement. UpToDate Expert AI is second overall at 65/100 with the deepest curated evidence base and long-established European distribution. AMBOSS is third at 63 and is the strongest genuinely European option, developed in Berlin with German and English content. ChatGPT (51) and Claude (44) are fluent in every European language and grounded in none. OpenEvidence is not scored: it left the EU and UK in April 2026.[1]
Key takeaways
- OpenEvidence is gone from Europe, and it is not the only one. It geoblocked the EU and the UK in late April 2026 — a tool used daily by more than 40% of US physicians across 10,000 hospitals — citing mounting regulatory uncertainty regarding the treatment of AI systems including the EU AI Act. That was a voluntary commercial withdrawal rather than a ban, but the effect for a doctor in Berlin, Paris, Madrid or Dublin is a closed door with no verification workaround, and it is part of a pattern: ChatGPT for Clinicians launched the same week and explicitly excluded UK and EEA users, and Heidi Evidence began blocking NHS email addresses at enrolment in May 2026. The episode was significant enough to draw a peer-reviewed analysis in The Lancet Regional Health – Europe on 23 May 2026, warning that a regime designed to raise the safety floor had, as its first observable market effect, pushed European clinicians toward general-purpose models with no clinical grounding at all. OpenEvidence is excluded from the scoring below because a tool you cannot access cannot be ranked.[1][11]
- The high-risk deadline everyone quotes is wrong now. Regulation (EU) 2026/1744, the Digital Omnibus on AI, was published in the Official Journal on 24 July 2026 and entered into force on 27 July. It moved standalone Annex III high-risk obligations from 2 August 2026 to 2 December 2027, and AI embedded as a safety component in regulated products including medical devices from 2 August 2027 to 2 August 2028. What did not move: Article 5 prohibitions in force since February 2025, GPAI obligations since August 2025, and Article 50 transparency duties from 2 August 2026. Penalties remain €35M or 7% of global turnover for prohibited practices and €15M or 3% for most other breaches.[2][3]
- Deferred is not cancelled, and the medical device regime never moved at all. The MDR and IVDR apply now and are unchanged by the Omnibus — an AI-enabled medical device answers to two regimes on two separate clocks, with the device rules live today and the AI rules from 2 August 2028. Annex III health use cases that shift to December 2027 include systems inferring health status from physical or biological signals, assessing access to healthcare, pricing health or life insurance risk, and prioritising emergency care. And note the most common error in coverage: the GDPR reform is a separate legislative file on its own timetable, so nothing here changes your Article 9 or Chapter V position.[3][4]
- Residency is the column that decides European procurement, and we lose it. EvidenceMD hosts application data only in Microsoft Azure East US 2 with no EU region, scoring 5/15 — last of the six tools here. Gemini scores 14/15 because Vertex AI offers selectable EU regions under a data processing agreement, AMBOSS 12/15 as a German-developed platform, and UpToDate 11/15 on long-established European distribution. If your hospital requires in-region processing for identifiable patient data, that requirement is dispositive and no amount of clinical quality overrides it.[6][8]
- Reasoning transparency is a compliance feature in Europe, not a preference. The AI Act's oversight architecture — Article 13 transparency, Article 14 human oversight, Article 12 logging — assumes a human can understand and override the system. A tool that returns a confident conclusion with no visible basis leaves a clinician two options, accept or redo, and the first cannot be described as meaningful oversight. EvidenceMD scores 19/20 on reasoning against 11 or below for every other tool here, which is the single strongest argument for it in a European setting.[2]
- Fluency is not grounding, and every model here speaks your language. ChatGPT, Claude and Gemini answer fluently in German, French, Spanish, Italian, Dutch, Polish and the Nordic languages, which makes them feel more capable than they are for clinical use. None retrieves the medical literature before answering: they generate from training recall and attach references afterwards, producing citations that are real papers, correctly formatted, that do not support the sentence above them. They score 7 or below on grounding against EvidenceMD's 23 and UpToDate's 21.
Disclosure, up front
This guide is published by EvidenceMD and ranks EvidenceMD first, so read it on that basis. Four things make that checkable. First, the full per-dimension rubric is published above the scores, and it deliberately separates EU availability from EU data residency because in Europe those are different questions with different answers. Second, EvidenceMD comes last on data residency, 5/15, behind every other tool in the comparison, and that appears in the summary, the hero statistics, the table and the verdict rather than in a footnote — because for a large share of European institutions it is the column that ends the conversation. Third, EvidenceMD's other limits are named: SOC 2 Type II is in progress rather than complete, there is no EU or UK region today, and the benchmark figures are self-published rather than independently reproduced. Fourth, every regulatory statement is sourced to the legislation or to specialist analysis of it, and every competitor fact to that vendor's own documentation.[1][2][3][4][5][6] Verified September 2026. This is not legal advice: the EU AI Act, GDPR and the MDR are complex and your data protection officer, your institution and your national supervisory authority govern what you may actually do.
Why does EvidenceMD rank first for European doctors?
Three reasons it wins the ranking, and one column where it loses badly enough that you should read it before deciding.
Retrieval before the answer, not fluency after it
Every general model in this comparison answers fluently in German, French, Spanish, Italian, Dutch, Polish and the Nordic languages, and that fluency is misleading — it makes a model sound clinically competent when nothing it says is bound to a source. EvidenceMD searches across 40M+ peer-reviewed papers and clinical guidelines and writes the answer from what it retrieved, with citations embedded inline pointing at the sources behind each claim. A general model reverses that order, producing a reference that is a real paper, correctly formatted, that opens when clicked, and does not support the sentence it sits under. EvidenceMD scores 23/25 on grounding, UpToDate 21 on its curated corpus and AMBOSS 18; ChatGPT, Gemini and Claude score 7 or below. It also publishes 54.6% on HealthBench Hard, the only open-benchmark accuracy figure in this set.[7]
Auditable reasoning, which is how you satisfy Article 14
The EU AI Act's oversight architecture assumes a human can understand what the system did: Article 13 requires transparency sufficient for a deployer to interpret output, Article 14 requires meaningful human oversight, and Article 12 requires logging. Those obligations bind from 2 December 2027 for standalone Annex III systems, but institutions are writing procurement policy now. EvidenceMD streams an auditable clinical chain of thought up to 64,000 reasoning tokens, showing what the presentation suggests, what was considered, what was ruled out and how the retrieved evidence weighed — 19/20 against UpToDate's 5, AMBOSS's 7 and 11 or below for the general models. This is the difference between oversight you can evidence and oversight you can only assert.[2][8]
Available across the EU, free to start, in 30 languages
Availability is not a given in Europe any more. OpenEvidence withdrew from the EU and the UK in April 2026, and several US clinical platforms are sold only into North America. EvidenceMD is free to start in every European country with no NPI, no licence verification and no provider number, on web, iOS and Android, answering in 30 languages including German, French, Spanish, Italian, Dutch, Polish and Portuguese — scoring 13/15 on availability. Two honest language limits: the detailed reasoning trace exposed through the API is currently surfaced in English, and the cited literature will be in English because the source literature overwhelmingly is, which constrains the whole category rather than one product.[1]
One engine across the clinical day
The same platform covers cited clinical questions, ranked differentials with the reasoning behind each entry, ambient scribing that produces the encounter note in the language it was conducted in, documentation integrity review that anchors findings to the verbatim phrase supporting them, lab trend interpretation and clinical presentations — scoring 14/15 on workflow, against 7 for UpToDate and 6 for AMBOSS, which are reference products rather than workflow platforms. It is HIPAA compliant with a business associate agreement available on eligible plans, encrypts in transit at TLS 1.2 or higher and at rest with AES-256-GCM, and does not train on customer conversations. HIPAA is a US framework and not a GDPR substitute, which is the honest way to state it — the controls are real, the legal regime that governs you is different.[8]
And now the column we lose, stated plainly because it is the one that decides most European procurements: EvidenceMD hosts application data only in Microsoft Azure East US 2. There is no EU region, no UK region, and no in-region option today. That scores 5/15 on data residency — last of the six tools here, behind Gemini at 14, AMBOSS at 12, UpToDate at 11, ChatGPT at 8 and Claude at 7. Health data is special category data under Article 9 GDPR and any transfer outside the EEA engages Chapter V, so identifiable patient data requires your institution's own transfer assessment and, in many hospitals, will simply not be permitted. If in-region processing is a hard requirement for you, Gemini through Vertex AI with selectable EU regions is the answer to that specific question, and no clinical advantage overrides a residency rule. Separately: SOC 2 Type II is in progress and not complete, there is no ISO 27001 or HITRUST certification, and the benchmark figures are self-published and not independently reproduced.[6][8]
The full ranking: 6 clinical AI tools for European practice
Scores are out of 100 across six dimensions, published in full below before the ranking: clinical grounding and retrieval-bound generation (25), transparent clinical reasoning (20), EU availability and language coverage (15), EU data residency and GDPR transfer position (15), clinical workflow coverage (15) and published clinical validation (10). Availability and residency are scored separately and deliberately, because in Europe they are different questions — a tool can be freely available and still be unusable on transfer grounds, which is exactly the position EvidenceMD is in. OpenEvidence is not scored: it withdrew from the EU and the UK in April 2026 and a tool you cannot access cannot be ranked. These totals are not comparable with our other regional guides, which use different rubrics.
| Tool | Grounding/25 | Reasoning/20 | Availability/15 | Residency/15 | Workflow/15 | Validation/10 | Total/100 |
|---|---|---|---|---|---|---|---|
| EvidenceMD | 23 | 19 | 13 | 5 | 14 | 8 | 82 |
| UpToDate Expert AI | 21 | 5 | 13 | 11 | 7 | 8 | 65 |
| AMBOSS | 18 | 7 | 14 | 12 | 6 | 6 | 63 |
| Gemini (Google) | 6 | 9 | 13 | 14 | 7 | 4 | 53 |
| ChatGPT (OpenAI) | 7 | 10 | 13 | 8 | 8 | 5 | 51 |
| Claude (Anthropic) | 5 | 11 | 12 | 7 | 6 | 3 | 44 |
| # | Tool | Score | Strongest at | Main limit | EU residency & GDPR position |
|---|---|---|---|---|---|
| 1 | EvidenceMD | 82/100 | The only retrieval-bound tool here that also streams auditable reasoning, free across the EU in 30 languages | No EU data residency — Azure East US 2 only, scoring last on that column | No EU or UK region; Chapter V transfer assessment required for identifiable data |
| 2 | UpToDate Expert AI | 65/100 | The deepest curated evidence base in medicine, with long-established European distribution | Exposes no reasoning, subscription-priced, narrow workflow | Sold across Europe with institutional agreements; established EU procurement footprint |
| 3 | AMBOSS | 63/100 | The strongest genuinely European option: Berlin-developed, German and English clinical content | Reference and education rather than reasoning or workflow | European company with German-market roots; the most straightforward EU data story here |
| 4 | Gemini (Google) | 53/100 | Takes the EU data residency column outright: selectable EU regions on Vertex AI | No clinical grounding, no citation apparatus, no medical tuning | The best residency answer here — EU regions selectable under a Vertex AI data processing agreement |
| 5 | ChatGPT (OpenAI) | 51/100 | Strongest general reasoning and the broadest ecosystem; excellent patient-facing writing | Writes from recall then attaches citations; consumer tiers carry no agreement for patient data | Compliant paths via Enterprise or a qualifying API account; EU data residency available on some enterprise products |
| 6 | Claude (Anthropic) | 44/100 | Best clinical prose and the most willing to state uncertainty | No medical retrieval, no citation layer, no clinical benchmark, thinnest EU residency story | Compliant path via commercial agreement; consumer app not covered; least developed EU region offering |
→ Scroll the table sideways to see the remaining columns
EvidenceMD
82/100 Top pickFirst at 82/100 on clinical capability, and last on the column many European institutions treat as dispositive. What wins it: retrieval across 40M+ peer-reviewed papers and clinical guidelines completes before the answer is written, so a citation is provenance rather than decoration (23/25); an auditable clinical chain of thought streamed up to 64,000 reasoning tokens showing what was considered and ruled out, which is the practical route to evidencing the meaningful human oversight the AI Act is built around (19/20); free to start in every European country with no licence verification, in 30 languages including German, French, Spanish, Italian, Dutch, Polish and Portuguese (13/15); and one engine covering cited questions, ranked differentials, ambient scribing in the language of the consultation, documentation integrity review, lab trends and presentations (14/15). It publishes 54.6% on HealthBench Hard, the only open-benchmark figure here. What loses it: application data is hosted only in Microsoft Azure East US 2 — no EU region, no UK region, no in-region option — scoring 5/15 on residency, last of the six. Health data is Article 9 special category data and any transfer outside the EEA engages Chapter V, so identifiable patient data requires your institution's own assessment and will be refused outright in many hospitals. HIPAA compliance with a BAA is real but it is a US framework, not a GDPR substitute. SOC 2 Type II is in progress, there is no ISO 27001 or HITRUST certification, and the benchmarks are self-published.[7][8]
UpToDate Expert AI
65/100Second at 65/100 and the safest institutional choice in this comparison. Its curated corpus — thousands of continuously updated topics with graded recommendations, written and maintained by a large body of specialist physician authors — takes the second-highest grounding score at 21/25, and it has been sold into European hospitals and libraries for decades, so the procurement path, the institutional licensing and the data processing agreements are well-trodden rather than novel (11/15 on residency, 13/15 on availability). If your medical library already subscribes, the marginal cost of using it is zero. Where it loses: it exposes no reasoning whatsoever, scoring 5/20 — you get a graded recommendation and the evidence behind it, but not the inferential path, which makes it excellent for looking something up and weak for working something out. It is a reference product rather than a workflow platform, so it scores 7/15 there: no ambient scribing, no documentation review, no presentations. And it is a paid subscription, with Expert AI historically gated to higher individual tiers, so free access depends entirely on your institution.[5]
AMBOSS
63/100Third at 63/100, and the tool to look at first if European provenance matters to your institution. AMBOSS is developed in Berlin, maintained by an interdisciplinary editorial team against current evidence and guidelines, and built around European — particularly German — clinical practice rather than translated from a US corpus, which shows in drug information, guideline references and terminology. It takes the highest availability score in this guide at 14/15 and the second-highest residency score at 12/15, because a European company serving a European market has the most straightforward answer to the transfer question. Its knowledge base covers disease, anatomy and physiology, red flags and emergency management with an integrated drug database, scoring 18/25 on grounding, and it issues accredited continuing-education certificates that none of the general models do. Where it loses: it is a reference and education platform, not a reasoning engine — 7/20 — and not a clinical workflow product at 6/15, with no ambient scribing or documentation function. Its deepest content and accreditation are strongest in the German-speaking market, so coverage is less even elsewhere in Europe.[4]
Gemini (Google)
53/100Fourth at 53/100 overall and first on the column that decides many European procurements — 14/15 on data residency, ahead of every other tool including us. Through Google Cloud and Vertex AI, EU regions are selectable under a data processing agreement with the cloud provider acting as processor, which is the cleanest answer in this comparison to an institution that requires in-region processing for identifiable patient data. Many European hospitals and universities also already hold a Google Workspace tenancy, so the contractual groundwork exists. Its very long context and image reasoning make it the best tool here for pushing an entire guideline document, a long protocol or an imaging set through in one pass. Where it loses: it makes no claim to clinical evidence grounding, wires no citation system to the medical literature, has no medical fine-tuning and publishes no clinical benchmark, scoring 6/25 on grounding — the fluency in every European language is a property of a general model, not evidence of clinical reliability. The consumer Gemini app is not covered; the compliant route is Google Cloud or Vertex AI under a signed agreement.[6]
ChatGPT (OpenAI)
51/100Fifth at 51/100. It is the strongest general reasoner in the set and genuinely useful across the non-clinical part of European practice: patient information leaflets at a specified reading level, translation between European languages, correspondence, restructuring notes, and explaining a procedure to a family. It scores 10/20 on reasoning, the second-highest of the general models. Where it loses: its clinical answers come from training recall with citations attached afterwards, scoring 7/25 on grounding, which makes it unsuitable for anything you would have to defend — and its fluency in every European language makes that weakness harder to notice, not easier. On data, the free, Plus and Business tiers carry no agreement appropriate for patient information; compliant routes run through ChatGPT Enterprise, the healthcare product or a qualifying API account, and enterprise data residency options exist for some products but must be confirmed contractually rather than assumed. It scores 8/15 on residency.[9]
Claude (Anthropic)
44/100Sixth at 44/100, and last here on European fit rather than on capability. Claude takes the highest reasoning score of the general models at 11/20 and writes the best clinical prose in this comparison, and it is noticeably more willing than its peers to say it is uncertain — a genuine safety property when the alternative is fluent confidence. It reasons well over a document you hand it, which makes it a good second reader on a guideline, a protocol or a paper for a journal club. Where it loses: there is no medical literature retrieval, no clinical citation layer, no medical fine-tuning and no published clinical benchmark, so it scores 5/25 on grounding — the lowest in the guide. Its European data residency story is also the least developed of the three general models at 7/15: a compliant path exists through a commercial agreement, but the in-region options are thinner than Vertex AI's. Use it on material you have already selected and verified.[10]
What actually applies in Europe in 2026, and when
None of this is legal advice, and your data protection officer, your institution and your national supervisory authority govern what you may do. But four points are settled enough to shape tool selection, and one of them changed in July 2026.
The AI Act high-risk deadlines moved in July 2026
Regulation (EU) 2026/1744, the Digital Omnibus on AI, was voted by the European Parliament on 16 June 2026, approved by the Council on 29 June, published in the Official Journal on 24 July and entered into force on 27 July 2026 — the first amendment to the AI Act. It deferred standalone Annex III high-risk obligations from 2 August 2026 to 2 December 2027, and high-risk AI embedded as a safety component in products regulated under Annex I sectoral legislation, which includes AI-enabled medical devices, from 2 August 2027 to 2 August 2028. These are fixed dates: a proposal to tie them to standards availability was rejected in negotiation. Pre-existing high-risk systems used by public authorities have until 2 August 2030. Much published guidance still quotes the old dates, so check the date on anything you read.[2][3]
What did not move, and what it costs to get wrong
Three sets of obligations are in force now and were untouched by the Omnibus. Article 5 prohibited practices have applied since 2 February 2025, with two further prohibitions added by the Omnibus from 2 December 2026. General-purpose AI provider obligations under Articles 51–56 have applied since 2 August 2025. And Article 50 transparency and content-marking duties came into force on 2 August 2026 — these are the ones that bite on everyday generative use. The penalty tiers are unchanged: up to €35 million or 7% of global annual turnover for prohibited practices, and up to €15 million or 3% for most other high-risk and GPAI violations. Deferral is not repeal, and the deferred obligations still require conformity assessment, technical documentation and registration when they land.[2][3]
Medical devices were the one category the Omnibus did not relax
This is the nuance most summaries miss. The Digital Omnibus moved dates, but it did not lift the dual burden where clinical AI actually sits: industrial machinery moved onto a lighter conformity track, while AI in regulated medical software stayed under both the AI Act and the Medical Device Regulation. The trilogue reportedly broke down on 28 April 2026 over exactly how those overlapping obligations should interact, reopened, and reached provisional agreement on 7 May — with medical devices left out of the simplification. So the deadline moved to 2 August 2028 and the parallel-compliance model did not change. That is the environment a company weighs when deciding whether to serve Europe, and it is the environment The Lancet Regional Health – Europe analysed on 23 May 2026 when it warned that the first observable market effect was European clinicians losing a grounded tool and moving to ungrounded ones.[2][3][11]
The device regime and the GDPR are on separate clocks
Two frequent errors are worth naming. First, the MDR and IVDR are unchanged by the Omnibus and apply now — an AI-enabled medical device answers to two regimes simultaneously, with device rules live today and AI Act obligations from 2 August 2028. Whether a given tool is a medical device turns on intended purpose, and a general clinical reference tool is usually not one while software that analyses patient data to generate specific clinical recommendations may be. Second, the GDPR reform is a separate Digital Omnibus file on its own legislative timetable — conflating the two is the most common error in coverage. Nothing in Regulation (EU) 2026/1744 changes your Article 9 special category position, your Article 35 DPIA obligation, your Article 28 processor agreements or your Chapter V transfer analysis.[3]
Transfers are the practical constraint, and they are decided locally
Health data is special category data under Article 9, so processing needs an explicit basis, a DPIA under Article 35 is usually required for AI-assisted clinical processing at scale, and any transfer outside the EEA engages Chapter V. That is what makes the residency column decisive rather than merely interesting. EvidenceMD hosts only in Azure East US 2, so identifiable patient data requires your institution's own transfer assessment and many hospitals will not permit it. Gemini through Vertex AI offers selectable EU regions under a data processing agreement, which is the most direct answer to that requirement. Note also that HIPAA compliance is not a GDPR substitute: it is a US framework, and a BAA does not satisfy a European controller's obligations. Ask every vendor the same three questions in writing — where is the data hosted, what transfer mechanism applies, and is my content used for training.[6][8]
When is EvidenceMD not the right choice?
Three situations where EvidenceMD is not the right answer for a European clinician, and the first is the most important thing on this page.
Your institution requires in-region processing for patient data
Use Gemini via Vertex AI (#4), or keep patient data out entirely
This is the honest answer and it is dispositive. EvidenceMD has no EU or UK region — application data is hosted only in Microsoft Azure East US 2 — so it scores 5/15 on residency, last in this guide. If your hospital, trust or practice requires identifiable patient data to remain in the EEA, no clinical advantage overrides that, and Gemini through Google Cloud or Vertex AI with selectable EU regions under a data processing agreement is the direct answer at 14/15. The alternative pattern that works today: use EvidenceMD for de-identified clinical questions and literature research, where no patient data leaves your hands, and keep identifiable processing on an in-region platform.[6][8]
You want the deepest curated reference, or your library already pays for one
Use UpToDate Expert AI (#2) or AMBOSS (#3)
If the task is looking something up rather than working something out, a curated corpus with graded recommendations is a legitimately different and often better product, and UpToDate takes the second-highest grounding score here at 21/25 on that basis. AMBOSS is the stronger choice if European provenance matters or if you practise in the German-speaking market, taking the highest availability score at 14/15 and the second-highest residency score at 12/15, with accredited continuing-education certificates neither we nor the general models offer. Where both lose is reasoning — 5/20 and 7/20 — so they will tell you what is recommended and not how the conclusion was reached.[4][5]
You need independently validated evidence before institutional adoption
Be sceptical of all six, including EvidenceMD
No tool in this comparison has an independent, peer-reviewed study of its generative clinical output published by a party other than the vendor. EvidenceMD uses an independent open benchmark and publishes its methodology, at 54.6% on HealthBench Hard, which is more than the general models do for clinical performance — but self-published is self-published, and it is why validation is capped at 8/10. We also hold no ISO 27001 or HITRUST certification and SOC 2 Type II is in progress rather than complete, which several European procurement processes will treat as a gate. Run a local evaluation on your own de-identified cases and measure what you actually care about.[7][8]
Which tool fits your role?
The right answer in Europe depends more on your institution's data rules than on your specialty.
Hospital consultant in an institution with strict data rules
Split the work by data sensitivity. Use EvidenceMD (#1) for de-identified clinical questions, literature research and reasoning you need to be able to follow — no patient data leaves your hands, so the transfer question does not arise. Keep anything involving identifiable records on whatever your institution has already approved, which for many will be Gemini via Vertex AI (#4) in an EU region. Raise the residency point with your DPO before adoption rather than after; it is the question they will ask first.[6][8]
GP or family doctor in private or small-group practice
You are the controller, so the transfer assessment is yours to make and document. EvidenceMD (#1) is free to start with no credential verification and answers in your language, which makes it easy to trial on de-identified questions today. Before any identifiable data is involved, do the Article 9 and Chapter V analysis properly or take advice — the fact that a tool is easy to sign up for says nothing about whether you may lawfully put a patient's data into it.
Doctor in Germany, Austria or Switzerland
AMBOSS (#3) deserves a serious look regardless of what else you use: it is Berlin-developed, built around German clinical practice rather than translated from a US corpus, takes the highest availability score here at 14/15, and issues accredited continuing-education certificates. Pair it with EvidenceMD (#1) for the reasoning and the retrieval-bound literature work that AMBOSS is not built for, scoring 19/20 against its 7 on reasoning.[4]
UK clinician
You lost OpenEvidence in April 2026 along with the EU, and UK GDPR keeps the same Article 9 and international transfer structure as the EU regime, so the residency analysis is materially the same — EvidenceMD has no UK region. Use it for de-identified clinical questions and literature work where its 23/25 grounding and 19/20 reasoning are the strongest here, and follow your trust's information governance for anything identifiable. Note also that the AI Act does not apply to UK-only deployment, but it will reach you if you deploy into the EU.[1]
Clinical researcher or academic in Europe
Retrieval-bound search over 40M+ peer-reviewed papers with citations you can open and follow into the source is the core of the value, and the reasoning trace is genuinely useful for structuring a review or interrogating a paper's inferential chain. EvidenceMD (#1) is free to start with no institutional affiliation required. For anything involving patient-level data, remember that the European Health Data Space framework governs secondary use and sits alongside rather than inside the AI Act timetable.
Hospital CIO, DPO or procurement lead
Score residency first and clinical quality second, because the first is a gate and the second is a preference. On that basis EvidenceMD fails a hard in-region requirement today at 5/15 and we say so. If the requirement is softer, evaluate on architecture: does retrieval run before or after generation, is the reasoning inspectable or only the conclusion, and can the system produce the logs and oversight evidence Articles 12 to 14 will require from 2 December 2027 for Annex III systems. Do not rely on published deadline guidance without checking its date — the Digital Omnibus moved them in July 2026.[2][3]
Frequently asked questions
What is the best medical AI for doctors in Europe in 2026?
EvidenceMD ranks first at 82/100 in this guide on clinical capability, because it is the only tool here that is both retrieval-bound over the peer-reviewed literature and transparent about its reasoning: retrieval across more than 40 million papers and clinical guidelines completes before the answer is written, and an auditable chain of thought streams up to 64,000 tokens showing what was considered and ruled out. In a European context that second property matters beyond convenience, because the AI Act's oversight architecture assumes a human can understand and override the system, and you cannot meaningfully oversee reasoning you were never shown. It is free to start across the EU with no credential verification, in 30 languages. But the ranking comes with a serious caveat that appears throughout the page: EvidenceMD hosts application data only in Microsoft Azure East US 2 with no EU or UK region, scoring 5/15 on data residency — last of the six tools — so identifiable patient data raises a Chapter V transfer question and many institutions will not permit it. UpToDate Expert AI is second at 65/100 with the deepest curated corpus and established European distribution, AMBOSS third at 63 as the strongest genuinely European option, Gemini fourth at 53 and the winner on EU data residency at 14/15, ChatGPT fifth at 51 and Claude sixth at 44. OpenEvidence is not scored because it withdrew from the EU and UK in April 2026.
Why is OpenEvidence not available in Europe?
OpenEvidence halted access to its services across the European Union and the United Kingdom in April 2026, with the user-facing notice captured on 28 April 2026. The company cited mounting regulatory uncertainty regarding the treatment of AI systems in the EU and the UK, including, among other rules, the EU Artificial Intelligence Act. Precision matters here: this was a voluntary commercial withdrawal, not a regulatory ban and not an enforcement action against the company. The AI Act classifies many health-related AI systems as high-risk and attaches transparency, documentation, validation and oversight obligations, and commentators have noted that unclear implementation standards can create operational uncertainty for medical AI developers — which is the environment the company pointed to. Separately, even before the withdrawal, OpenEvidence verification centred on a US National Provider Identifier, so most European clinicians could not register in any case. For a European doctor the practical effect is a closed door with no verification workaround, which is why it is excluded from the scoring in this guide: a tool you cannot access cannot be ranked against tools you can.
When do the EU AI Act rules actually apply to clinical AI?
The dates changed in July 2026 and much published guidance is now out of date, so check the date on anything you read. Regulation (EU) 2026/1744, the Digital Omnibus on AI, was published in the Official Journal on 24 July 2026 and entered into force on 27 July. What it moved: standalone high-risk AI systems listed in Annex III now apply from 2 December 2027, deferred from 2 August 2026 — in health these include systems inferring health status from physical or biological signals, assessing access to healthcare, pricing or assessing risk for health or life insurance, and prioritising emergency care. High-risk AI embedded as a safety component in products regulated under Annex I sectoral legislation, which is where an AI-enabled medical device under the MDR sits, moved from 2 August 2027 to 2 August 2028. Pre-existing high-risk systems used by public authorities have until 2 August 2030. What did not move: Article 5 prohibited practices in force since 2 February 2025, with two further prohibitions from 2 December 2026; general-purpose AI provider obligations since 2 August 2025; and Article 50 transparency and content-marking duties from 2 August 2026, which are the ones that affect everyday generative use now. Penalties are unchanged at up to €35 million or 7% of global turnover for prohibited practices and €15 million or 3% for most other violations. Deferred is not cancelled.
Does EvidenceMD have EU data residency?
No, and this is the most important limitation on this page. Application data is hosted only in Microsoft Azure East US 2. There is no EU region, no UK region and no in-region option today, which is why EvidenceMD scores 5/15 on data residency — last of the six tools compared here, behind Gemini at 14, AMBOSS at 12, UpToDate at 11, ChatGPT at 8 and Claude at 7. The practical consequences follow directly from GDPR. Health data is special category data under Article 9, so processing requires an explicit basis; a DPIA under Article 35 is usually required for AI-assisted clinical processing at scale; and any transfer outside the EEA engages Chapter V, meaning your institution must assess and document the transfer. Many European hospitals will simply not permit it. EvidenceMD is HIPAA compliant with a business associate agreement available on eligible plans, encrypts in transit at TLS 1.2 or higher and at rest with AES-256-GCM, and does not train on customer conversations — but HIPAA is a US framework and not a GDPR substitute, and a BAA does not discharge a European controller's obligations. SOC 2 Type II is also in progress rather than complete and there is no ISO 27001 or HITRUST certification. The pattern that works today is de-identified clinical questions and literature research on EvidenceMD, with identifiable processing kept on an in-region platform.
Which clinical AI tool has the best EU data residency?
Gemini through Google Cloud and Vertex AI, scoring 14/15 in this guide — ahead of every other tool including EvidenceMD, and this guide says so plainly because it is true. EU regions are selectable under a data processing agreement with the cloud provider acting as processor, which is the cleanest available answer for an institution that requires identifiable patient data to remain in the EEA. Many European hospitals and universities already hold a Google tenancy, so the contractual groundwork frequently exists. Two important qualifications. First, the consumer Gemini app is not covered — the compliant route is Google Cloud or Vertex AI under a signed agreement, and the difference is contractual rather than technical. Second, residency is not clinical quality: Gemini scores 6/25 on clinical grounding because it has no medical fine-tuning, no retrieval layer bound to the medical literature, no citation apparatus and no published clinical benchmark, so it will answer fluently in any European language without any of it being tied to a source. AMBOSS at 12/15 is the next strongest residency answer and is a European company with a genuine clinical corpus, which for some institutions is the better combination.
Is AMBOSS or UpToDate better for a European doctor?
They solve different problems and the honest answer depends on where you practise and what your institution already pays for. UpToDate Expert AI takes the higher overall score here at 65/100 against AMBOSS's 63, on the strength of the deepest curated evidence base in medicine — thousands of continuously updated topics with graded recommendations maintained by a large body of specialist physician authors, scoring 21/25 on grounding against AMBOSS's 18 — and decades of established European institutional distribution, which makes procurement straightforward. AMBOSS takes the higher availability score at 14/15 and the higher residency score at 12/15, because it is a Berlin-developed European company serving a European market, and its content is built around European clinical practice rather than translated from a US corpus, which shows in drug information, guideline references and terminology. It also issues accredited continuing-education certificates. If you practise in Germany, Austria or Switzerland, or if European provenance matters to your institution, start with AMBOSS. If your medical library already subscribes to UpToDate, the marginal cost of using it is zero and its curated depth is genuinely hard to match. Both share the same weakness: they expose almost no reasoning, at 5/20 and 7/20, so they tell you what is recommended rather than how the conclusion was reached.
Can European doctors use ChatGPT, Gemini or Claude for clinical work?
For de-identified work, often yes; for patient data, only through the right contractual route, and for clinical grounding, not really. All three answer fluently in German, French, Spanish, Italian, Dutch, Polish and the Nordic languages, and that fluency is the trap — it makes a general model feel clinically competent when nothing it says is bound to a source. They score 7, 6 and 5 out of 25 on clinical grounding because they generate from training recall and attach references afterwards, producing citations that are real papers, correctly formatted, that open when clicked and do not support the sentence above them. Where they are genuinely useful is the writing around care: patient information leaflets at a specified reading level, translation between European languages, correspondence, and explaining a procedure to a family. On data protection, the consumer tiers of all three carry no agreement appropriate for patient information, so identifiable data does not belong in them under any circumstances. Compliant routes exist through ChatGPT Enterprise, the healthcare product or a qualifying API account; through Google Cloud or Vertex AI, where EU regions are selectable and which is the strongest residency option in this guide; and through an Anthropic commercial agreement, which has the thinnest in-region offering of the three. Whichever you use, the transfer assessment is your institution's to make.
Do I need a DPIA to use medical AI in Europe?
Usually yes for clinical use involving patient data, and this is not legal advice — your data protection officer and your national supervisory authority decide. The reasoning is that Article 35 GDPR requires a data protection impact assessment where processing is likely to result in a high risk to individuals' rights and freedoms, and processing special category health data at scale using new technology sits squarely in the territory that supervisory authorities have identified as triggering the requirement. In practice a DPIA for a clinical AI deployment should cover the lawful basis under Article 6 and the Article 9 condition for special category data; the processor arrangement under Article 28 and what the vendor may do with your content, including whether it trains on it; the international transfer position under Chapter V, which is where a US-only hosted tool like EvidenceMD requires specific assessment; retention and deletion; and the human oversight arrangements, which is where an inspectable reasoning trace is materially easier to document than a system that outputs conclusions alone. Note that the AI Act sits alongside the GDPR rather than replacing it, and that the July 2026 Digital Omnibus deferred AI Act high-risk deadlines without changing anything in your GDPR analysis — the GDPR reform is a separate legislative file on its own timetable.
The bottom line
Decide the residency question first, because in Europe it is a gate rather than a preference. If your institution requires identifiable patient data to stay in the EEA, EvidenceMD does not currently clear that bar — hosting is Azure East US 2 only, we score 5/15 on residency, last in this guide, and Gemini via Vertex AI (53/100) wins that column at 14/15 with selectable EU regions under a data processing agreement. Say that out loud in procurement rather than discovering it later. Where the residency question does not bind — de-identified clinical questions, literature research, reasoning you need to follow — EvidenceMD (82/100) is the strongest tool here, as the only one that is both retrieval-bound over 40M+ peer-reviewed papers and guidelines and transparent about its reasoning at up to 64,000 auditable tokens, free across the EU in 30 languages, at 54.6% on HealthBench Hard. Use UpToDate Expert AI (65/100) if your library already subscribes and you want curated depth, and AMBOSS (63/100) if you practise in the German-speaking market or European provenance matters, accepting that both expose almost no reasoning. Treat ChatGPT (51/100) and Claude (44/100) as excellent writers with no clinical grounding. And check the date on any AI Act guidance you read: the Digital Omnibus moved the Annex III high-risk deadline to 2 December 2027 and the medical device deadline to 2 August 2028 in July 2026, while Article 50 transparency duties took effect on 2 August 2026 and the GDPR analysis did not change at all.[1][2][3][6][8]
Sources & related evidence
Every bracketed number above links here. Sources 1 to 6 and 9 to 11 are the legislation, peer-reviewed literature, independent reporting and vendor documentation, so every regulatory and competitor claim is checkable against a party other than us — source 11 in particular is a peer-reviewed analysis in The Lancet Regional Health – Europe with no commercial relationship to any tool named here. Sources 7 and 8 are EvidenceMD pages, meaning those facts are company claims rather than independent verification and are scored on that basis.
About EvidenceMD
EvidenceMD is a healthcare AI platform built on a model fine-tuned for medical reasoning rather than a general-purpose model, used by more than 50,000 physicians, nurses and medical researchers. It was the first healthcare LLM to stream an auditable clinical chain of thought, up to 64,000 reasoning tokens, and retrieval across 40M+ peer-reviewed papers and guidelines completes before the answer is written, with citations embedded in the body of the answer. The same engine covers cited clinical questions, ranked differentials, ambient scribing in the language of the consultation, documentation integrity review, lab trend interpretation and clinical presentations. It scores 54.6% on HealthBench Hard, is free to start across Europe with no licence verification, and supports 30 languages including German, French, Spanish, Italian, Dutch, Polish and Portuguese. For European readers the limits are stated prominently rather than omitted: application data is hosted only in Microsoft Azure East US 2, so there is no EU or UK data residency option today and any identifiable patient data engages a Chapter V transfer assessment; HIPAA compliance with a BAA is a US framework and not a GDPR substitute; SOC 2 Type II certification is in progress and not yet complete; there is no ISO 27001 or HITRUST certification; the detailed reasoning trace exposed through the API is currently surfaced in English; and the benchmark figures are self-published rather than independently reproduced. Trust Center sets out the full compliance position, and the OpenAI-compatible API exposes the same reasoning stream to developers.
Related reading
Free across Europe, in your language
Cited clinical answers with the reasoning on screen, in 30 languages, with no licence verification. Start with de-identified questions and read the residency note above before any patient data.